Translating neuroscience discoveries into effective therapies remains challenging: in 2024, only around 7% of drug trials resulted in approved treatments, often due to preclinical models failing to capture the complexity of the human brain. Conventional in vitro systems frequently lack the cellular diversity and interactions necessary to reflect disease biology, limiting their predictive power and reproducibility. This…

Arctoris is featured as a series partner in the Biology for a Better Tomorrow digital series, an initiative created with the Royal Society of Biology to highlight how biological sciences are addressing global challenges and advancing innovation across healthcare, sustainability, and environmental protection. The series brings together researchers, academic institutions, and biotechnology companies to showcase…

Arctoris was featured in Fierce Biotech following the acquisition of Eli Lilly’s Life Sciences Studio, a highly automated robotic laboratory originally based in San Diego. The facility’s automation platform is being relocated to Arctoris’ headquarters in Oxford, significantly expanding the company’s experimental capacity. The Life Sciences Studio was initially developed by Eli Lilly as part…

Arctoris was featured in Labiotech, in an article highlighting a collaboration between the Oxford-based automation company and Swiss software firm Molecule. The partnership aims to improve drug discovery by combining laboratory automation with digital tools designed to simplify the sharing and development of drug intellectual property. The collaboration addresses a key challenge facing the pharmaceutical…

Arctoris was featured in a Drug Discovery World (DDW) webinar discussing how automated experimentation platforms can accelerate drug discovery, particularly during urgent global health challenges such as the COVID-19 pandemic. The presentation highlights how automated laboratory workflows can enable scientists to rapidly generate high-quality experimental data while maintaining reproducibility and scalability. By integrating robotics, automated…

Arctoris was featured in Fierce Biotech following a period of significant growth, highlighting the company’s expansion and the development of a strengthened executive leadership team. The article reports that Arctoris co-founder Tom Fleming, Ph.D., has taken on the role of CEO, succeeding co-founder Martin-Immanuel Bittner, M.D., Ph.D., who led the company from 2018 to early…

Arctoris has been featured by Formic Ventures following the firm’s investment in the company. Formic Ventures is a venture capital firm focused on supporting biotechnology startups and innovations that can improve human health and longevity. The investment reflects confidence in Arctoris’ automated drug discovery platform, which combines robotics, advanced data generation, and scientific expertise to…

Arctoris is featured in a video from the Royal Society of Biology’s Biology for a Better Tomorrow series exploring how technological innovation is transforming the drug discovery process. The video highlights the longstanding challenges in pharmaceutical R&D, where traditional approaches to drug discovery are often slow, manual, and resource-intensive. Emerging technologies such as laboratory automation,…

Arctoris was featured in a Labiotech article exploring how automation technologies are transforming cancer research. The piece highlights how robotic laboratories and digital experiment management platforms can help researchers conduct complex biological experiments more efficiently. The article describes Arctoris’ vision of enabling scientists to run experiments remotely through an automated research platform. Researchers can configure…

Arctoris was featured in an article by Nanalyze examining the growing role of automation in life sciences laboratories. The piece explores how robotic experimentation and automated laboratory platforms are transforming drug discovery by enabling faster, more reproducible research. As pharmaceutical R&D becomes increasingly data-driven, laboratory automation allows scientists to run experiments at greater scale and…